Clear eyes MAXIMUM REDNESS RELIEF — Class II drug recall D-1825-2019
Terminated recall by Medtech Products, Inc., reported 2019-08-28, distributed nationwide. CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the
| Recall number | D-1825-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Medtech Products, Inc., Tarrytown, NY, United States |
| Recall initiated | 2019-07-26 |
| Classified | 2019-08-16 |
| Reported by FDA | 2019-08-28 |
| Terminated | 2021-03-10 |
| Distributed | Nationwide (US) |
| Countries outside the US | BB, GY, JM |
| Quantity | 1,872,984 bottles |
| Reason classes | cgmp |
| UPC / GTIN / UDI-DI | 00678112665778 |
| Lot numbers | 08/19, 10/19, 11/19, 16234, 16247, 16286, 16314 |
Product
Clear eyes MAXIMUM REDNESS RELIEF (Glycerin 0.5%, Naphazoline hydrochloride 0.03%) eye drops, 0.5 FL OZ (15 mL) bottle, Distributed by Medtech Products Inc., Tarrytown, NY 10591, A Prestige Brands Company, UPC 6 78112 66577 8.
Reason for recall
CGMP Deviations: concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility that could impact the product quality of the finished products.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1825-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.